Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
7.38
+0.16 (2.22%)
At close: Dec 20, 2024, 4:00 PM
7.49
+0.11 (1.49%)
After-hours: Dec 20, 2024, 6:57 PM EST
Iovance Biotherapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for IOVA stock have an average target of 23.33, with a low estimate of 10 and a high estimate of 34. The average target predicts an increase of 216.12% from the current stock price of 7.38.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 6, 2024.
Analyst Ratings
The average analyst rating for IOVA stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 5 | 5 | 5 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +333.60% | Nov 6, 2024 |
| UBS | UBS | Strong Buy Initiates $17 | Strong Buy | Initiates | $17 | +130.35% | Oct 24, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +333.60% | Aug 12, 2024 |
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $19 → $10 | Buy → Hold | Downgrades | $19 → $10 | +35.50% | Jul 29, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +333.60% | Jun 28, 2024 |
Financial Forecast
Revenue This Year
164.78M
from 1.19M
Increased by 13,758.70%
Revenue Next Year
447.61M
from 164.78M
Increased by 171.64%
EPS This Year
-1.29
from -1.89
EPS Next Year
-0.80
from -1.29
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 176.0M | 499.0M | 970.6M | |||
| Avg | 164.8M | 447.6M | 710.3M | |||
| Low | 150.5M | 145.1M | 295.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 14,704.0% | 202.8% | 116.8% | |||
| Avg | 13,758.7% | 171.6% | 58.7% | |||
| Low | 12,555.2% | -11.9% | -34.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.89 | -0.24 | 0.30 | |||
| Avg | -1.29 | -0.80 | -0.25 | |||
| Low | -1.37 | -1.25 | -0.86 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.